Atrial Fibrillation
Conditions
Keywords
post-operative atrial fibrillation, transcutaneous (tragus) vagal nerve stimulation, outcomes
Brief summary
Patients undergoing cardiac surgery are at high risk of developing atrial fibrillation (AF), with estimated rates of 30-50% and occurs at approximately 2-4 days after surgery. The autonomic nervous system is known to play a key role in AF. Animal studies have indicated that duration and inducibility of AF can be decreased with intermittent vagus nerve stimulation (VNS). In humans, literature suggests that transcutaneous (tragus) VNS (tVNS) can serve as a potentially non-invasive therapy for treatment of post-operative AF (POAF) by reducing inflammation and increasing atrial refractory period. The purpose of this study is to determine the value of tVNS in reducing the burden of POAF and days of hospitalization after cardiac surgery.
Detailed description
The trial will have two study arms: active tVNS vs. sham tVNS. Patients will be randomized to active tVNS vs. sham tVNS and will receive optimal post-op care in both arms. Active tVNS (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. For sham tVNS, Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-op day 0. Stimulation will continue until 5 days post-op or discharge. Discomfort threshold will be determined in both arms pre-operatively in the conscious state. This current will be used for stimulation for this patient until they are awake and extubated after surgery. The stimulation threshold may be reassessed once the patient is able to provide feedback. Patients will be approached and recruited prior to their scheduled cardiac surgery. Recruited patients who give informed consent will have the discomfort stimulation threshold (current that leads to discomfort at the tragus) determined prior to surgery. Post-operatively, stimulation will be performed in the tVNS group at just below discomfort threshold. In the sham group, the stimulator will be turned on but current set at 0 mA. Stimulations will be performed within 12 hours of arrival to the ICU after surgery, and then twice a day between the hours of 7:00-9:00 am and 6:00-8:00 pm. If POAF develops in either arm, stimulation will be continued for the full 5 days. Ten ml of blood will be drawn within 12 hours of arrival to the ICU after surgery and on day 3 post-op for measurement of biomarkers. Serum will be stored at -80 Celsius and processed in batches of 10-15 samples. Sample Size: The investigators expect cardiac surgery to be associated with 40% incidence of POAF. The investigators expect tVNS to reduce this incidence by 40%. A sample size of 133 subjects per arm will be able to achieve 80% power at alpha of 0.05. If interim analysis is planned, Pocock method will be used and a p value of 0.03 will be used for interim and 0.03 for final analysis. Data will be analyzed according to the intention-to-treat principle. Randomization: A 1:1 randomization ratio for the tVNS vs. sham will be utilized. Patients who meet all of the inclusion and none of the exclusion criteria will be randomized in the order of their enrollment. After completing the Informed Consent process, the subject is then randomized following completion of the baseline and demographics information case report forms. Randomization should occur prior to any study-related tests or procedures. The subjects will be considered enrolled in the study once randomization has occurred. Randomization will be stratified by clinical center and post-operative amiodarone use. A computer-generated randomization list with random permuted block of a variable will be produced for each clinical center. Investigators and other study staff members should not be able to identify the study assignment until this time. If a randomization assignment is inadvertently disclosed prior to use, the assignment will never be used. A report of randomization compliance will be generated at the conclusion of the study.
Interventions
DEVICEactive tVNS
20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
DEVICEsham tVNS
Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
Sponsors
University of California, Los Angeles
University of Oklahoma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients scheduled to undergo coronary artery bypass surgery, major vascular/aneurysm repair requiring bypass, valvular replacement or repair, or both, for clinically indicated reasons. 2. Age ≥ 18 years. 3. Sinus rhythm at baseline. 4. Provision of signed informed consent and stated willingness to comply with all study procedures for duration of the study
Exclusion criteria
1. Emergent surgery 2. Anticipated amiodarone use 3. Patients with permanent or persistent atrial fibrillation 4. Planned concomitant atrial Maze procedure 5. Complex congenital heart disease 6. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal). 7. Left ventricular assist device or status post orthotopic heart or lung transplantation 8. Unable or unwilling to comply with protocol requirements. 9. Known channelopathy such as Brugada syndrome, long QT syndrome, or Catecholaminergic monomorphic ventricular tachycardia 10. Symptomatic sinus bradycardia or sinus node dysfunction at baseline without an implantable pacemaker. 11. Complete heart block or trifascicular block without an implantable pacemaker 12. Recurrent vasovagal syncope 13. Unilateral or bilateral vagotomy 14. Chronic amiodarone use
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Atrial Fibrillation | 6 days | Incidence of post-operative atrial fibrillation for postoperative day 0-5 (postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Days of Hospitalization | Postop day 0 until discharge from the hospital, an average of 1 week. | Number of days in the hospital from postoperative day 0 to discharge. |
| Inflammatory Markers | Within 12 hours of arrival to the ICU after surgery and on postop day 3 (2 days) | Reduction in inflammatory markers including C-reactive protein (CRP), Interleukin 10 (IL-10), Tumour Necrosis Factor alpha (TNF-alpha), Interleukin 6 (IL-6), and Interleukin 1 beta (IL-1β) |
| Sympathetic Neural Markers | Postop day 3 (1 day) | Reduction in sympathetic neural markers including norepinephrine, Neuropeptide Y (NPY), and galanin. |
| Pain Assessment | 6 days | Pain scores will be assessed on postoperative days 0-5 using the visual analog score (Scale 0-10). Zero for no pain and ten being the worst pain experienced. They will be obtained and recorded into the medical record by the nurse monitoring the subject as part of standard care. Postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day. |
| Narcotic Usage | 6 days | The number of participants in each group that had narcotic usage reported (Y/N) postoperatively. Postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day. |
| Duration of Post-op Atrial Fibrillation | 6 days | How many hours or days for each incidence of postoperative atrial fibrillation for postoperative days 0-5 (postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day). |
| Heart Rate During Atrial Fibrillation | 6 days | The heart rate during each incidence of postoperative atrial fibrillation for postop days 0-5 (postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day). |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJonathan Ho, MD
University of California, Los Angeles
PRINCIPAL_INVESTIGATORMarmar Vaseghi, MD
University of California, Los Angeles
PRINCIPAL_INVESTIGATORStavros Stavrakis, MD, PhD
University of Oklahoma
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 62 years STANDARD_DEVIATION 12.3 |
| Body Mass Index (BMI) | 28.1 kg/m^2 STANDARD_DEVIATION 5.7 |
| Race and Ethnicity Not Collected | 0 Participants |
| Sex: Female, Male Female | 15 Participants |
| Sex: Female, Male Male | 62 Participants |
| Surgery Type 0 | 47 Participants |
| Surgery Type 1 | 12 Participants |
| Surgery Type 2 | 2 Participants |
| Surgery Type 3 | 3 Participants |
| Surgery Type 4 | 1 Participants |
| Surgery Type 5 | 0 Participants |
| Surgery Type 6 | 0 Participants |
| Surgery Type 7 | 2 Participants |
| Surgery Type 8 | 2 Participants |
| Surgery Type 9 | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 37 | 0 / 40 |
| other Total, other adverse events | 9 / 37 | 13 / 40 |
| serious Total, serious adverse events | 0 / 37 | 0 / 40 |
Outcome results
None listed